BACKGROUND: There are a limited number of approved treatments for @entity6509 ( @entity6509 ) and remission is difficult to maintain after successful treatment. OBJECTIVES: To investigate remission over a 36-week extension period in @entity1 with moderate to severe @entity6509 successfully treated with 16 weeks' treatment with @entity3070 1% cream once daily (QD) or @entity868 0.75% cream twice daily (BID) in a randomized, parallel-group Phase III study. METHODS: Treatment was discontinued in @entity1 initially successfully treated [Investigator's Global Assessment (IGA) score of 0 or 1] with @entity3070 1% cream QD (n = 399) or @entity868 0.75% cream BID (n = 365; Part A) and @entity1 were followed every 4 weeks for up to 36 weeks (Part B). Treatment with the same study treatment as used in Part A was only re-initiated if @entity1 relapsed (IGA >=  2). Efficacy assessments were: time to first relapse; relapse rate; and number of days free of treatment. Safety assessments included incidence of adverse events and local cutaneous signs and symptoms. RESULTS: The median time to first relapse was significantly longer (115 days vs. 85 days) and relapse rates at the end of the study period significantly lower (62.7% vs. 68.4%) for @entity1 initially successfully treated with @entity3070 1% compared with @entity868 0.75%; Kaplan-Meier plot demonstrated a statistically significant difference between the two arms (P = 0.0365). The median number of days free of treatment was higher for @entity3070 compared with @entity868 (196 days vs. 169.5 days; P = 0.026). The percentage of @entity1 who experienced a related adverse event was equally low in both groups. CONCLUSION: The results of this relapse study showed that an initial successful treatment with @entity3070 1% cream QD significantly extended remission of @entity6509 compared with initial treatment with @entity868 0.75% cream BID following treatment cessation.

Maintenance of remission following successful treatment of @entity6509 with XXXX 1% cream vs. @entity868 0.75% cream: 36-week extension of the ATTRACT randomized study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity868 :: ('MESH:D008795', 'Chemical') :: ['metronidazole'] @entity3070 :: ('MESH:D007559', 'Chemical') :: ['ivermectin'] @entity6509 :: ('MESH:D012393', 'Disease') :: ['PPR', 'papulopustular rosacea', 'rosacea']
@entity3070 :: (MESH:D007559,Chemical) :: ['ivermectin']
